Cormac Cosgrove

Cormac Cosgrove

Auto-generated profile, based on publicly available information

Cormac Cosgrove

Oncology Discovery Research, AbbVie Inc., North Chicago, Illinois

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Blood Advances
Verified
Journal Article
Closed access
PDF file
CFCatherine Forconi
Catherine Forconi
CCCormac P. Cosgrove
Cormac P. Cosgrove
PSPryia Saikumar-Lakshmi
Pryia Saikumar-Lakshmi
CNChristina E. Nixon
Christina E. Nixon
JFJoslyn Foley
Joslyn Foley
AMAnn Moormann
Ann Moormann
Natural killer (NK) cells are critical for restricting viral infections and mediating tumor immunosurveillance. Epstein-Barr virus (EBV) and Plasmodium falciparum malaria are known risk factors for endemic Burkitt lymphoma (eBL), the most common childhood cancer in equatorial Africa. To date, the composition and function of NK cells have not been evaluated in eBL etiology or pathogenesis. Therefore, using multiparameter flow cytometry and in vitro killing assays, we compared NK cells from healthy children and children diagnosed with eBL in Kenya. We defined 5 subsets based on CD56 and CD16 expression, including CD56negCD16pos. We found that licensed and terminally differentiated perforin-expressing CD56negCD16pos NK cells accumulated in eBL children, particularly in those with high EBV loads (45.2%) compared with healthy children without (6.07%) or with (13.5%) malaria exposure (P = .0007 and .002, respectively). This progressive shift in NK cell proportions was concomitant with fewer CD56dimCD16pos cells. Despite high MIP-1β expression, CD56negCD16pos NK cells had diminished cytotoxicity, with lower expression of activation markers NKp46, NKp30, and CD160 and the absence of TNF-α. Of note, the accumulation of poorly cytotoxic CD56negCD16pos NK cells resolved in long-term eBL survivors. Our study demonstrates impaired NK cell–mediated immunosurveillance in eBL patients but with the potential to restore a protective NK cell repertoire after cancer treatment. Characterizing NK cell dysfunction during coinfections with malaria and EBV has important implications for designing immunotherapies to improve outcomes for children diagnosed with eBL. Key Points Terminally differentiated CD56neg NK cells expand in children after chronic malaria exposure and in those diagnosed with eBL. NK cells in eBL patients express high levels of MIP-1β in lieu of TNF-α, and normal NK cell profiles appear to be restored in eBL survivors. Visual Abstract

1 March 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
EDEmilia R. Dellacecca
Emilia R. Dellacecca
CCCormac Cosgrove
Cormac Cosgrove
ZMZhussipbek Mukhatayev
Zhussipbek Mukhatayev
SASuhail Akhtar
Suhail Akhtar
VEVictor H. Engelhard
Victor H. Engelhard
IPI. Caroline Le Poole
I. Caroline Le Poole

15 December 2011 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
CCCormac Cosgrove
Cormac Cosgrove
Stuart GallowayStuart Galloway
Stuart Galloway
CNCraig Neal
Craig Neal
Angus HunterAngus Hunter
Angus Hunter
BMBrian Keith McFarlin
Brian Keith McFarlin
EKEmmanuel Katsanis
Emmanuel Katsanis

1 June 2020 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
FHFei Han
Fei Han
EDEmilia R. Dellacecca
Emilia R. Dellacecca
LBLevi W. Barse
Levi W. Barse
CCCormac Cosgrove
Cormac Cosgrove
SHSteven W. Henning
Steven W. Henning
IPI. Caroline Le Poole
I. Caroline Le Poole
Patients with lymphangioleiomyomatosis (LAM) develop pulmonary cysts associated with neoplastic, smooth muscle–like cells that feature neuroendocrine cell markers. The disease preferentially affects premenopausal women. Existing therapeutics do not cure LAM. As gp100 is a diagnostic marker expressed by LAM lesions, we proposed to target this immunogenic glycoprotein using TCR transgenic T cells. To reproduce the genetic mutations underlying LAM, we cultured Tsc2−/− kidney tumor cells from aged Tsc2 heterozygous mice and generated a stable gp100-expressing cell line by lentiviral transduction. T cells were isolated from major histocompatibility complex–matched TCR transgenic pmel-1 mice to measure cytotoxicity in vitro, and 80% cytotoxicity was observed within 48 hours. Antigen-specific cytotoxicity was likewise observed using pmel-1 TCR-transduced mouse T cells, suggesting that transgenic T cells may likewise be useful to treat LAM in vivo. On intravenous injection, slow-growing gp100+ LAM-like cells formed lung nodules that were readily detectable in severe combined immunodeficient/beige mice. Adoptive transfer of gp100-reactive but not wild-type T cells into mice significantly shrunk established lung tumors, even in the absence of anti–PD-1 therapy. These results demonstrate the treatment potential of adoptively transferred T cells to eliminate pulmonary lesions in LAM.

9 June 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ACAdam S. Chervin
Adam S. Chervin
JSJennifer D. Stone
Jennifer D. Stone
IKIwona Konieczna
Iwona Konieczna
KCKelly M. Calabrese
Kelly M. Calabrese
NWNingyan Wang
Ningyan Wang
EREdward B. Reilly
Edward B. Reilly
CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to a CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector T cells enabling redirected T cell–mediated killing of tumor cells. Although the majority of CD3 bispecific molecules in clinical development incorporate tumor-targeting antibody-based binding domains, many tumor-associated antigens derive from intracellular proteins and are not accessible to targeting via antibody. Intracellular proteins processed into short peptide fragments and presented on the cell surface by MHC proteins are recognized by T-cell receptors (TCR) on the surface of T cells. Here we describe the generation and preclinical evaluation of ABBV-184, a novel TCR/anti-CD3 bispecific composed of a highly selective soluble TCR that binds a peptide derived from the oncogene survivin (BIRC5) bound to the class I MHC allele human leukocyte antigen (HLA)-A*02:01 expressed on tumor cells, linked to a specific binder to the CD3 receptor on T cells. ABBV-184 drives an optimal distance between T cell and target cell thereby enabling sensitive recognition of low-density peptide/MHC targets. Consistent with the expression profile of survivin across a broad range of both hematologic and solid tumors, treatment of acute myeloid leukemia (AML) and non–small cell lung cancer (NSCLC) cell lines with ABBV-184 results in T-cell activation, proliferation, and potent redirected cytotoxicity of HLA-A2–positive target cell lines, both in vitro and in vivo, including patient-derived AML samples. These results indicate that ABBV-184 is an attractive clinical candidate for the treatment of patients with AML and NSCLC.

15 July 2018 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
JEJonathan M. Eby
Jonathan M. Eby
ASAngela R. Smith
Angela R. Smith
TRTimothy P. Riley
Timothy P. Riley
CCCormac Cosgrove
Cormac Cosgrove
CAChristian M. Ankney
Christian M. Ankney
IPI. Caroline Le Poole
I. Caroline Le Poole